The antiviral drug Remdesivir reduces recovery time in coronavirus sufferers, according to research results published Friday night.
The study, conducted by the United States National Institute of Allergy and Infectious Diseases (NIAID), was published by the New England Journal of Medicine.
On May 1, the United States authorized the use of remdesivir in hospitals in an emergency, a measure that Japan also took and that Europe could also adopt.
The study found that remdesivir, injected intravenously over 10 days, speeds the recovery of patients hospitalized for COVID-19, compared to using a placebo.
The clinical tests were carried out with more than a thousand patients in ten different countries.
On April 29, NIAID Director Anthony Fauci, the visible face of the Donald Trump administration in managing the pandemic, said preliminary evidence showed that remdesivir had a clear, significant, and positive effect on reducing the time of recovery. ”
However, the study authors indicate that the drug cannot prevent deaths.
“Given the high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is probably not sufficient, “.